A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abm6420
Abstract: The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses… read more here.
Keywords: cell; suppressive myeloid; myeloid cells; immune suppressive ... See more keywords
IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-21-0457
Abstract: An IDO-specific peptide vaccine is demonstrated to target IDO+ cells, enhancing vaccine-induced immune responses against non-IDO tumor antigens. These effects reduce tumor growth and inhibit immune-suppressive myeloid populations in multiple tumor models. read more here.
Keywords: suppressive myeloid; tumor; myeloid populations; ido ... See more keywords